Recombinate Side Effects
Generic Name: antihemophilic factor,antihemophilic factor (human),antihemophilic factor (recombinant)
Please note - some side effects for Recombinate may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Recombinate Side Effects - for the Professional
Recombinate
Adverse Reactions from Clinical Trials
During controlled clinical studies with Recombinate enrolling 210 subjects, the most commonly reported adverse drug reactions were chills, flushing, rash and epistaxis..
| System Organ Class (SOC) |
Preferred MedDRA Term |
Number of Subjects | Percent of Evaluable Subjects* |
| GASTROINTESTINAL DISORDERS | Nausea | 1 | 0.48 |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS |
Chills Fatigue Pyrexia |
3 1 1 |
1.43 0.48 0.48 |
| INFECTIONS AND INFESTATIONS | Ear infections | 1 | 0.48 |
| INVESTIGATIONS | Acoustic stimulation tests abnormal | 1 | 0.48 |
| MUSCULOSKELETAL AND CONNECTIVE TISSUES DISORDERS | Pain in extremity | 1 | 0.48 |
| NERVOUS SYSTEM DISORDERS |
Dizziness Tremors |
1 1 |
0.48 0.48 |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | Pharyngolaryngeal pain | 1 | 0.48 |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS |
Hyperhidrosis Pruritus Rash Rash maculopapular |
1 1 2 1 |
0.48 0.48 0.95 0.48 |
| VASCULAR DISORDERS |
Epistaxis Flushing Hematoma Hypotension Pallor Peripheral coldness |
1† 2 1 1 1 1 |
0.48 0.95 0.48 0.48 0.48 0.48 |
During the Previously Treated Patients (PTP) study, none of the 71 subjects developed de novo evidence of Factor VIII inhibitor. However, during the phase II/III portion of the study, 1 subject with a history of inhibitors exhibited inhibitor activity at 6 months (0.8 Bethesda Units [BU]), which resolved by 9 months. One other subject in this study had detectable Factor VIII inhibitor at baseline (1.26 BU) and exhibited an anamnestic response at 6 months (10.3 BU). During a prospective pharmaco-surveillance study of subjects who received batches of Recombinate containing modestly increased Chinese Hamster Ovary (CHO) cell protein levels, none of the 34 treated subjects developed a Factor VIII inhibitor.
During the Previously Untreated Patients (PUP) study, 22 of the 73 evaluable subjects developed inhibitors to Factor VIII. Of these, 13 subjects displayed no detectable Factor VIII inhibitors at study exit.
Post-Marketing Adverse Reactions
In addition to the adverse reactions noted in clinical trials, the following adverse reactions have been reported in the post-marketing experience. These adverse reactions are listed by MedDRA (version 12.1) System Organ Class (SOC), then by MedDRA coding system Preferred Term in order of severity.
BLOOD AND LYMPHATIC SYSTEM DISORDERS: Factor VIII inhibition
CARDIAC DISORDERS: Tachycardia, Cyanosis
GASTROINTESTINAL DISORDERS: Vomiting, Abdominal pain
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Malaise, Injection site reactions, Chest pain, Chest discomfort
IMMUNE SYSTEM DISORDERS: Anaphylactic reaction, Hypersensitivity
NERVOUS SYSTEM DISORDERS: Loss of consciousness, Headache, Paresthesia
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS: Dyspnea, Cough, Laryngeal edema
SKIN AND SUBCUTANEOUS TISSUE DISORDERS: Angioedema, Urticaria, Erythema
TopSide Effects by Body System - for Healthcare Professionals
Nervous system
Nervous system side effects have included headache, dizziness, somnolence, and asthenia.
Respiratory
Respiratory side effects have included dyspnea and rhinitis.
Musculoskeletal
Musculoskeletal side effects have included arthralgia.
Local
Local side effects have included injection site pain.
General
General side effects have included pyrexia and chills.
Gastrointestinal
Gastrointestinal side effects have included nausea, diarrhea, and vomiting.
Dermatologic
Dermatologic side effects have include pruritus, rash, and urticaria.
Cardiovascular
Cardiovascular side effects have included hemorrhage, hypotension, and vasodilatation.
TopMore Recombinate resources
- Recombinate Advanced Consumer (Micromedex) - Includes Dosage Information
- Recombinate Prescribing Information (FDA)
- Antihemophilic Factor Professional Patient Advice (Wolters Kluwer)
- Advate Consumer Overview
- Advate Prescribing Information (FDA)
- Advate MedFacts Consumer Leaflet (Wolters Kluwer)
- Antihemophilic Factor (Human) Monograph (AHFS DI)
- Antihemophilic Factor (Recombinant) Monograph (AHFS DI)
- Helixate FS Prescribing Information (FDA)
- Kogenate Consumer Overview
- Kogenate FS MedFacts Consumer Leaflet (Wolters Kluwer)
- Kogenate FS Prescribing Information (FDA)
- Monoclate-P Prescribing Information (FDA)
- Xyntha Prescribing Information (FDA)
- Xyntha Consumer Overview
- Xyntha MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
